THE IMPORTANCE OF ARTIFICIAL INTELLIGENCE TECHNOLOGIES IN THE EARLY DETECTION OF CERVICAL CANCER: INTERNATIONAL EXPERIENCE AND OPPORTUNITIES FOR THE NATIONAL HEALTHCARE SYSTEM
Keywords:
cervical cancer, human papillomavirus (HPV), screening, colposcopy, artificial intelligence, machine learning, digital diagnostics, UzbekistanAbstract
Cervical cancer (CC) remains one of the most serious threats to women’s health, particularly in low- and middle-income countries, where late-stage diagnosis continues to be associated with high mortality rates. According to international epidemiological data, a significant proportion of cervical cancer cases can be prevented through effective screening programs, vaccination against the human papillomavirus (HPV), and timely detection of precancerous lesions.
Conventional diagnostic methods currently used in clinical practice—cytological examination, colposcopy, and visual inspection—largely depend on the specialist’s experience, technical capabilities, and the level of healthcare infrastructure, which often leads to subjective diagnostic errors. In recent years, digital transformation and the implementation of artificial intelligence (AI) technologies have opened new scientific and practical opportunities for improving the early detection of cervical cancer.
AI-based diagnostic systems enable automated analysis of colposcopic images, improve the accuracy of triage among HPV-positive women, and reduce errors associated with the human factor. This article analyzes current scientific evidence on the application of artificial intelligence technologies in cervical cancer screening, evaluates their comparative effectiveness in relation to traditional diagnostic methods, and discusses prospects for their implementation in the healthcare system of the Republic of Uzbekistan based on international experience.
References
Тилляшайхов М.Н., Ибрагимов Ш.Н., Джанклич С.М. Состояние онкологической помощи населению республики Узбекистан в 2023 году. – Ташкент: ИПТД «Халк», 2024, - с.184.
American Society for Colposcopy and Cervical Pathology (ASCCP). 2019 Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests. Journal of Lower Genital Tract Disease. 2020;24(2):102–131.
Arbyn M., Ronco G., Anttila A., Meijer C.J.L.M., Poljak M., Ogilvie G. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2020;38(42):6392–6400.
Bray F., Laversanne M., Weiderpass E., Soerjomataram I. The ever-increasing importance of cancer registry data: cervical cancer as an example. International Journal of Cancer. 2021;148(12):2955–2963.
Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., Wentzensen N. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease. 2020;24(2):102–131.
Zakhirova , NN, Tillyashaykhov , MN, Adylkhodjaev , AA, Akhmedov , OM, Osmanova , EZ, Saydakhmedova , VA, & Raximov , NM (2022). EXPERIENCE OF THE NATIONAL VACCINATION PROGRAM IMPLEMENTATION AGAINST HUMAN PAPILLOMA VIRUS IN THE REPUBLIC OF UZBEKISTAN. World Bulletin of Public Health , 13 , 126-131.
Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249.
World Health Organization. Cervical cancer elimination initiative: global strategy and goals for 2030. Geneva: WHO; 2021.
